Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03920995 · ClinicalTrials.gov registry record
Multi-center Database Registry to Study Thalamus Changes Using AI in MS
A clinical trial of Multiple Sclerosis, sponsored by University at Buffalo.
- Completed
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT03920995: Completed study of Multiple Sclerosis, sponsored by University at Buffalo.
NCT03920995 is a study of Multiple Sclerosis that has completed, run by University at Buffalo. The registered enrollment target is 1,000 participants, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (72% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03920995, a study of Multiple Sclerosis, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study the Investigator's propose to validate a newly developed approach, DeepGRAI (Deep Gray Rating via Artificial Intelligence), to simplify the calculation of thalamic atrophy in a clinical routine and allow academic and community neurologists to plan, perform, and publish novel and influential clinical research using data from clinical routine, by employing deep machine learning (DML) pattern recognition (PR) information through use of artificial intelligence (AI).
Primary Outcome
Measuring the ability of DeepGRAI to measure thalamus volume as a predictor of clinical outcomes for patients with multiple sclerosis
Conditions Studied
Study Locations (1)
New York
- University at Buffalo - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2023-10-31 |
What the finished NCT03920995 record still lists
NCT03920995 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (72% higher).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT03920995 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03920995 about?
NCT03920995 is a clinical study titled "Multi-center Database Registry to Study Thalamus Changes Using AI in MS". In this study the Investigator's propose to validate a newly developed approach, DeepGRAI (Deep Gray Rating via Artificial Intelligence), to simplify the calculation of thalamic atrophy in a clinical routine and allow academic and community neurologists to plan, perform, and publish novel and influe...
What is the current status of trial NCT03920995?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2020-04-01. Estimated completion is 2023-10-31.
What conditions does trial NCT03920995 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
Who is sponsoring clinical trial NCT03920995?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03920995 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03920995's enrollment target sits among peer trials
1,000 26th of 315 higher than 287 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI